BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 31842958)

  • 1. Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.
    Napolitano S; Matrone N; Muddassir AL; Martini G; Sorokin A; De Falco V; Giunta EF; Ciardiello D; Martinelli E; Belli V; Furia M; Kopetz S; Morgillo F; Ciardiello F; Troiani T
    J Exp Clin Cancer Res; 2019 Dec; 38(1):492. PubMed ID: 31842958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
    Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
    Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.
    Belli V; Matrone N; Napolitano S; Migliardi G; Cottino F; Bertotti A; Trusolino L; Martinelli E; Morgillo F; Ciardiello D; De Falco V; Giunta EF; Bracale U; Ciardiello F; Troiani T
    J Exp Clin Cancer Res; 2019 Jun; 38(1):236. PubMed ID: 31164152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
    Troiani T; Napolitano S; Martini G; Martinelli E; Cardone C; Normanno N; Vitagliano D; Morgillo F; Fenizia F; Lambiase M; Formisano L; Bianco R; Ciardiello D; Ciardiello F
    Clin Cancer Res; 2015 Sep; 21(18):4153-64. PubMed ID: 26019172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy.
    Yang M; Davis TB; Pflieger L; Nebozhyn MV; Loboda A; Wang H; Schell MJ; Thota R; Pledger WJ; Yeatman TJ
    BMC Cancer; 2022 Mar; 22(1):256. PubMed ID: 35272617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.
    Chuang J; Wang C; Guo Y; Valenzuela V; Wu J; Fakih M
    Clin Colorectal Cancer; 2021 Mar; 20(1):72-78. PubMed ID: 33436306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells.
    Cheon SK; Kim HP; Park YL; Jang JE; Lim Y; Song SH; Han SW; Kim TY
    Mol Oncol; 2018 Aug; 12(8):1398-1409. PubMed ID: 29896883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
    Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
    Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
    Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA
    Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
    Huang TY; Chang TC; Chin YT; Pan YS; Chang WJ; Liu FC; Hastuti ED; Chiu SJ; Wang SH; Changou CA; Li ZL; Chen YR; Chu HR; Shih YJ; Cheng RH; Wu A; Lin HY; Wang K; Whang-Peng J; Mousa SA; Davis PJ
    Cells; 2020 Aug; 9(8):. PubMed ID: 32756527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
    Peng S; Wang R; Zhang X; Ma Y; Zhong L; Li K; Nishiyama A; Arai S; Yano S; Wang W
    Mol Cancer; 2019 Nov; 18(1):165. PubMed ID: 31747941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity.
    Hong A; Piva M; Liu S; Hugo W; Lomeli SH; Zoete V; Randolph CE; Yang Z; Wang Y; Lee JJ; Lo SJ; Sun L; Vega-Crespo A; Garcia AJ; Shackelford DB; Dubinett SM; Scumpia PO; Byrum SD; Tackett AJ; Donahue TR; Michielin O; Holmen SL; Ribas A; Moriceau G; Lo RS
    Cancer Discov; 2021 Mar; 11(3):714-735. PubMed ID: 33318037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
    Suda K; Rozeboom L; Rivard CJ; Yu H; Ellison K; Melnick MAC; Hinz TK; Chan D; Heasley LE; Politi K; Mitsudomi T; Hirsch FR
    Lung Cancer; 2017 Jul; 109():1-8. PubMed ID: 28577937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
    Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
    Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
    Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
    Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.
    Yoon J; Koo KH; Choi KY
    Cancer Res; 2011 Jan; 71(2):445-53. PubMed ID: 21118963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.